Navigation Links
Monogram Announces 2008 Third Quarter Financial Results
Date:10/27/2008

- Conference call today at 4:30 p.m. ET -

SOUTH SAN FRANCISCO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today reported financial results for the quarter ended September 30, 2008.

The Company had revenues of $16.1 million for the third quarter of 2008, 55% higher than $10.4 million in the third quarter of 2007. This growth was driven by revenue from Trofile(TM) for selecting HIV patients to be treated with Selzentry(TM), Pfizer's CCR5 antagonist, and by revenue from use of Monogram's PhenoSense HIV(TM) resistance test and Trofile in a phase III trial by a pharmaceutical company customer.

Revenue for the nine months ended September 30, 2008 was $47.1 million, an increase of 60% over $29.5 million in the first nine months of 2007.

In addition to the reported revenue for the quarter, Monogram recorded as deferred revenue, the sale of Trofile assays to Pfizer for patient testing outside of the U.S. and for use in clinical trials. These deferred revenues were $1.6 million and $3.6 million for the three and nine months ended September 30, 2008, respectively. This revenue was recorded as deferred revenue due to the accounting for the Company's collaboration with Pfizer. Had these sales not been accounted for as deferred revenue, total revenue on a Non-GAAP basis, for the three and nine months ended September 30, 2008 would have been $17.7 million and $50.7 million, respectively.

Monogram has performed over 10,000 Trofile tests to date for U.S. patients and revenue from Trofile in the quarter ended September 30, 2008 was $4.8 million.

"Revenues were again at a record level in the third quarter," said Alfred Merriweather, Monogram's Chief Financial Off
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
10. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... -- EPFL and the University of  Geneva ... John P. Donoghue . The American neuroscientist is to ... The new Wyss Center for Bio- and ... , has named as its director one of ... , founder of Brown University,s Institute for Brain Science, ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3
... , ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) and ... entered into a licensing agreement for antibody therapeutic rights under ... Under the terms of the agreement, Affitech will license exclusive ...
... , ROCKVILLE, Md., July 22 ... selection of a Respiratory Syncytial Virus (RSV) vaccine candidate that ... Investigational New Drug (IND) application. As previously announced, Novavax ... of which have successfully induced antibody responses in mice. ...
... , , , ... Biotech, Inc., a company personalizing spine care through the development ... that they have entered into a collaboration that allows Axial ... Population Database (UPDB). UPDB is a genealogical and family history ...
Cached Biology Technology:Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 2Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 3Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 4Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech 5Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies 2Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies 3Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies 4Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders 2Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders 3
(Date:7/11/2014)... Wildlife Conservation Society shows that no-take zones in ... such as lobster, conch, and fish recover from ... areas. , The reporttitled "Review of the Benefits ... literature from no-take areas around the world. The ... recognized expert in marine protected areas and fisheries ...
(Date:7/11/2014)... July 11, 2014--Researchers at the Department of Energy,s ... 100 awards, presented by R&D Magazine in recognition ... "These awards recognize the tremendous value of our ... "Research and development at the National Labs continues ... and pursue the scientific and technological innovations necessary ...
(Date:7/11/2014)... fires burning in eastern New South Wales, Australia when ... At 03:35 UTC on July 11 (12:35 p.m. local ... over eastern New South Wales (NSW), the Moderate Resolution ... of the region and spotted smoke (light brown) from ... bands, are outlined in red. , The New South ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... ... Presidential Early Career Award for Scientists and Engineers (PECASE). The award ... scientists and engineers in the early stages of their careers. ... significant award," said Jane Lubchenco, Ph.D., under secretary of commerce for ...
... Researchers at the University of Missouri have identified a ... may provide new insight into the debilitating and fatal ... "Critical communication occurs at the point where nerves and ... nerves and muscles is disrupted, muscles do not work ...
... -- The National Institutes of Health (NIH) has awarded a ... research into risk factors for spina bifida and related congenital ... or brain is not fully enclosed. The research will ... E. Mason at Weill Cornell Medical College. Dr. Ross is ...
Cached Biology News:President to honor high achieving, early career NOAA scientists 2MU researchers find new insight into fatal spinal disease 2NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 2NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 3
Apoptosis Detection Systems and Reagents...
... plastic feeding tubes for rodent oral gavage ... risk of perforation and trauma. Plus they ... cleaning and the risk of cross-contamination. ... 20ga Length: ...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
...
Biology Products: